MBF THERAPEUTICS, INC.

AMBLER, PA · Founded 2008 · CIK 0001458729 · Biotech · Private

DNA vaccine delivered as intranasal spray using calcium phosphate nanoparticle-formulated plasmids encoding SARS-CoV-2 antigens

mbftherapeutics.com →
Grants
$256K
1 award
Sector median: 1
Raised
$2.0M
5 Form D · Jan 2024
33 months since last filing
Contracts
—
No federal contracts on record
Patents
4
1 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$100,000
Private capital raisedForm D · SEC$1,095,185
Private capital raisedForm D · SEC$130,000
Private capital raisedForm D · SEC$604,292
Federal grantNational Science Foundation · Phase I · STTR Phase I: Protective T Cell Vaccine for SARS CoV-2 (COVID-19)$256,000
Private capital raisedForm D · SEC$105,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1903SEQLL, LLC—$2.5M
1904NANOMEDTRIX LLC——
1905Hemispherian AS—$108K
1906MBF THERAPEUTICS, INC.—$2.0M
1907GRANNUS THERAPEUTICS, INC.—$1.8M
1908Mitera Biosciences Inc.—$1.7M
1909Regranion, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • Chris BungeDirector
  • Christopher CashmanDirector
  • Joseph ConnorDirector
  • Lorraine KellerExecutive Officer
  • Aris PersidisDirector
  • Christopher RaglandDirector
  • Dhiren ThakkerDirector
  • Thomas TillettDirector · Executive Officer

Patents

USPTO · 1 granted of 4

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.